ClinicalTrials.gg
RecruitingNCT06341803APIC-TMSUpdated Apr 2, 2024

Personalized Transcranial Magnetic Stimulation Treatment for Depression

An interventional study of Individually Neuronavigated accelerated intermittent theta burst stimulation with Magpro X100 in Depression, sponsored by Institute of Mental Health, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by Institute of Mental Health, Singapore · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Depression with a site in Singapore — 14 open to participants now, 18 under way, none of them phase 3. Depression · Singapore.

Planned enrollment
25th of 25
20 · median 122
Started
2024
with 4 others
No phase
23 of 34
11 open now
Primary completion
2025-04
later than 2 of 17 live
Registered
19th of 34
by date
Lead sponsor
7 of 34
Institute of Mental Health, Singapore

Among the 34 studies in Depression with a site in Singapore, this one is the 25th largest by planned enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2024, is one of 23 with no phase, reaches primary completion later than 2 of the 17 other live ones, and was the 19th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

14 of the 34 studies in Depression with a site in Singapore are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Depression with a site in Singapore, or all of them as a file.
02

Study summary

This proposal seeks to conduct a pragmatic single arm, open label pilot implementation to validate our individualized functional Magnetic Resonance Imaging (fMRI) connectome-guided localization approach for accelerated TMS among Asian patients with depression.

Participants will be patients with Major Depressive Disorder not responding to standard treatment, with no exclusions to fMRI or transcranial magnetic stimulation (TMS) (essentially metal implants in the head) and willing to participate in the pilot.

All participants will undergo MRI scans before and after the accelerated TMS treatment. The multi-session hierarchical Bayesian model (MS-HBM) approach will be used to estimate individualized connectome-guided target locations.

Patients will undergo accelerated TMS applied to individualized connectome-guided target locations (based on the MS-HBM approach).

Patients will undergo 10 sessions (each session lasting 10 min) spread out over 10 hours each day for 5 consecutive working days.

All clinical outcome data will be collected for each patient by a pre-defined questionnaire at four time points: at baseline, post-treatment, 1 month and 3 months during follow-up.

The clinical outcome data will be analyzed using linear regression or repeated analysis of variance (ANOVA) after adjusting for baseline clinical characteristics and socio-demographics. Trajectories of the clinical outcome data at baseline, post-treatment and all follow-up time points will be plotted and compared with time series statistical analysis models with the other clinical and socio-demographic characteristics included as confounders.

03

Conditions studied

  • Depression

Browse trials for

Keywords

  • neuronavigated
  • iTBS
  • Accelerated
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 21 years.
  2. diagnosis of current Major Depressive Episode.
  3. Montgomery-Asberg Depression Rating Scale score of 20 or more.
  4. Inadequate response to an adequate trial (4 weeks) of at least one antidepressant medication.
  5. Able to give .

Exclusion criteria

Exclusion Criteria:

  1. psychotic disorder
  2. Drug or alcohol abuse or dependence (preceding 3 months).
  3. Rapid clinical response required, e.g., high suicide risk.
  4. Significant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy.
  5. Metal in the cranium, skull defects, pacemaker, cochlear implant, medication pump or other electronic device.
  6. Pregnancy.
  7. Unsuitable for MRI.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Individually neuronavigated intermittent theta burst stimulation (Magpro X100) system for depression

    Participants will receive an accelerated intermittent theta burst stimulation (iTBS) treatment delivered with a MagVenture MagPro X100 system (MagVenture A/S, Denmark) equipped with a butterfly shaped MagVenture Cool-B65 A/P coil. The treatment course is comprised of 10 treatment sessions daily for 5 consecutive workdays for a total of 50 sessions. Each iTBS session is approximately 10 minutes (depth corrected Resting Motor Threshold of 90%, 60 cycles of 10 bursts of three pulses at 50 Hz, repeated at 5 Hz; 2s on and 8s off; 1800 pulses per session; with a 50-minute interval between sessions). All iTBS sessions will be performed by staff trained and credentialed in TMS according to Singapore College of Psychiatrists guidelines.

    Device: Individually Neuronavigated accelerated intermittent theta burst stimulation with Magpro X100

Interventions

  • DeviceIndividually Neuronavigated accelerated intermittent theta burst stimulation with Magpro X100

    MagproX 100 and Axilium Cobot with Localite camera

06

What researchers measure

Primary outcomes

  1. Montgomery-Åsberg Depression Rating Scale (MADRS)

    Clinician rated Depression rating scale, range of scores 0 to 60 with higher scores meaning a worse outcome

    Time frame: Baseline, immediately post treatment, 1 month and 3 months post intervention

Secondary outcomes

  1. Quick Inventory of Depressive Symptomatology (16-Item) (Self-Report) (QIDS-16)

    Patient rated Depression rating scale, scored 0-27 with higher scores meaning a worse outcome

    Time frame: Baseline, (Days 1-5 of treatment), immediately after intervention, 1 month and 3 months post intervention

  2. Montreal Cognitive Assessment (MoCA),

    global cognitive functioning, scored 0 to 30 with higher scores meaning better outcome

    Time frame: Baseline, immediately post treatment, 1 month and 3 months post intervention

  3. EuroQol- 5 Dimension (EQ-5D)

    Quality of life scales, Visual analogue scale 0-100 with higher scores meaning better outcome

    Time frame: Baseline, immediately post treatment, 1 month and 3 months post intervention

  4. Quality of Life Enjoyment and Satisfaction Questionnaire Short form (Q-LES-QS-SF)

    Quality of life scales, scored 0-70 with higher scores meaning better outcome

    Time frame: Baseline, immediately post treatment, 1 month and 3 months post intervention

Other outcomes

  1. Correlation of changes in functional connectivity with changes in MADRS scores

    Time frame: Baseline, immediately post treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Apr 2025, 13 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 13 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Apr 2, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Apr 1, 2025
CompletionEst.
Dec 31, 2025
Last update
Apr 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06341803
Lead sponsor
Institute of Mental Health, Singapore
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Mar 1, 2024
Primary completion
Apr 1, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 2, 2024

Study contacts

Phern Chern Tor, MBBS
Contact
phern_chern_tor@imh.com.sg
63892000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion